NCT04696029: DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
- State
- Under way
- Phase
- Phase 2
- People
- 118 planned
- Started
- 29 Mar 2021
- Primary completion
- Mar 2028
- Arms
- Difluoromethylornithine (DFMO)
- Results
- None posted
- 6 Jan 2021: Trial registered
- 29 Mar 2021: Trial started